C 19 H 19 N5O, triclinic, P¯ (no. 2), a = 11.8865(6) Å, b = 12.6289(7) Å, c = 13.5579 (7) 
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Source of material
The preparation of N′-(4-(dimethylamino)benzylidene)-5-phenyl-1H-pyrazole-3-carbohydrazide was done using our previous procedure [13] . 
Experimental details
Cell re nement and data reduction were carried out by Bruker SAINT [14] . The hydrogen atoms were 
placed on calculated positions with the help of the SHELX program (AFIX 43 or 137 option) [15] .
Discussion
Pyrazole derivatives are highlighted as important biologically active heterocyclic compounds. These derivatives show broad spectrum activity such as anti-in ammatory [1] , anti-oxidant [2] , antipyretic [3] , antimicrobial [4] , antiviral [5] , anticancer [6] , antitumor [7] , anticonvulsant [8] , analgesic [9] , antidepressant [10] , insecticides and fungicides [11, 12] . For this title structure, the asymmetric unit contains two independent molecules ( gure). All bond lengths and angles are in the expected ranges. The pyrazole ring (N1/N2/C7/C8/C9) makes the dihedral angles of 31.98 (2) 
